PLAY PODCASTS
Practical Application of Immuno-Oncology in RCC: Expert Discussion of Frontline Therapy
Episode 12

Practical Application of Immuno-Oncology in RCC: Expert Discussion of Frontline Therapy

Listen to Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for first-line immunotherapy treatment of advanced renal cell carcinoma.

Decera Clinical Education Oncology Podcast · Elizabeth R. Plimack MD MS, Martin H. Voss MD, Brian A. Costello MD

August 31, 202025m 42s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode, Elizabeth R. Plimack, MD, MS; Brian A. Costello, MD; and Martin H. Voss, MD, discuss current best practices for the first-line treatment of patients with metastatic renal cell carcinoma (RCC). Topics include:

  • Choice of first-line therapy
  • Combinations of targeted agents and immunotherapy
  • Combinations of immune checkpoint inhibitors
  • Active surveillance and monitoring
  • Cytoreductive nephrectomy

Presenters:

Elizabeth R. Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology 
Director, Genitourinary Clinical Research 
Professor, Department of Hematology/Oncology 
Fox Chase Cancer Center 
Temple Health 
Philadelphia, Pennsylvania

Brian A. Costello, MD
Associate Professor of Oncology and Urology
Division of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Martin H. Voss, MD
Clinical Director, Genitourinary Medical Oncology Service
Memorial Sloan Kettering Cancer Center
Assistant Professor 
Weill Cornell Medical College
New York, New York

Content based on an online CME program supported by educational grants from Eisai, Exelixis, Pfizer and EMD Serono, and Merck Sharp & Dohme Corp.

Link to full program: https://bit.ly/32IS9gx


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

brian costellonivolumabaxitinibpembrolizumabvegf targeted agentsimmuno-oncologymartin vossfirst-linerenal cell carcinomanephrectomyelizabeth plimackfrontlineipilimumabrccimmunotherapykidney cancer